2011-02-28 / 2011-03-01
Location: Cascais Portugal
EuroPLX began in 1995 and is an international platform for pharma and biopharma executives who are in charge of business development and licensing in and out of:
- approved patented or generic drugs
- medium to late stage (ph. II and up) drug developments
- OTC drugs and dietary supplements
- medical devices
- technologies applicable to marketed drugs or late stage drug developments.
EuroPLX Meetings feature a scope of collaborative agreements from patented to generic (incl. bio-generics and biosimilars), from prescription to OTC Drugs, from nutraceuticals to medical devices: development, licensing, marketing, promotion, and distribution.
In addition, attending companies frequently offer or look for R&D services, supporting technologies (drug delivery, medical devices), contract manufacture, and, to some extent, the supply of APIs and intermediates.
The actual focus of each meeting is determined by the participating companies’ business interests and is displayed as a "Dynamic Partnering Focus" onwww.europlx.com as delegates submit the necessary data.
The meeting frequency ( 3-4 times per year ) provides a time-to-market oriented instrument to follow up on negotiations in a timely manner.
PanGenerika will be attending EuroPLX 45 in Cascais, Portugal.